Gregory Gerboth, MD
Pulmonary Disease · Anchorage, AKNPI 1407838170
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 18 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Intuitive Surgical at 39.4% of the total.
Across 18 payments — averaging $30.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$216
- GSK$162
- Insmed, Inc.$53
- AstraZeneca$49
- Teva Pharmaceuticals USA, Inc.$42
- Boehringer Ingelheim$15
- plus $12 from 1 others
What the payments were for
- Food & beverage$53497%
- Education$163%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 4 | $216 |
| GSK | 4 | $162 |
| Insmed, Inc. | 3 | $53 |
| AstraZeneca | 3 | $49 |
| Teva Pharmaceuticals USA, Inc. | 2 | $42 |
| Boehringer Ingelheim | 1 | $15 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few pulmonary disease providers in Alaskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 104 | $1,628,108 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 424 | $506,324 |
| Spiriva RespimatTiotropium Bromide | 154 | $155,649 |
| Breo ElliptaFluticasone/Vilanterol | 204 | $145,362 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 141 | $107,079 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 123 | $103,523 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 104 | $90,231 |
| FasenraBenralizumab | 14 | $78,223 |
| Pirfenidone | 22 | $63,061 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 48 | $44,316 |
| NucalaMepolizumab | 11 | $40,344 |
| Advair HfaFluticasone Propion/Salmeterol | 62 | $37,589 |
| Spiriva HandihalerTiotropium Bromide | 35 | $36,467 |
| SymbicortBudesonide/Formoterol Fumarate | 106 | $35,940 |
| Arnuity ElliptaFluticasone Furoate | 71 | $31,383 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $15 | $1,935,152447 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Nucala, Arnuity Ellipta | $162 | $855,947888 claims |
| AstraZenecaBreztri Aerosphere, Fasenra, Symbicort, Pulmicort Flexhaler, Bevespi Aerosphere | $49 | $238,005275 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $42 | $10,01021 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pulmonary disease providers in Alaskaon file to place this against a meaningful peer group, so we don't.
Other pulmonary disease in Anchorage
- Marek MartynowiczAnchorage$12K
- Dustin McLemoreAnchorage$1K
- John ClarkAnchorage$975
- Kent StuberAnchorage$862
- Denise WurthAnchorage$352
- David ZielkeAnchorage$219
- Beth BakerAnchorage$74
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.